Breaking News Instant updates and real-time market news.

TRVN

Trevena

$6.03

0.11 (1.86%)

13:03
10/19/16
10/19
13:03
10/19/16
13:03

Meet Trevena: A talk with CEO Maxine Gowen

Trevena (TRVN) is a clinical-stage biopharmaceutical company focused on the development of therapeutics that target G protein coupled receptors, or GPCRs, for the treatment of acute pain. In an exclusive interview with The Fly, the company's CEO Maxine Gowen talked about the company's ongoing clinical trials, upcoming events, market opportunity for its lead drug and much more. Here are some of the highlights: OLICERIDINE TRIALS ON TRACK: Phase 3 trials for the company's primary candidate Oliceridine, or TVR130, for the treatment of moderate to severe acute pain continue to be on track, with top line data still expected in the first quarter of 2017, CEO Gowen said. According to the executive, Trevena believes it will have sufficient data to support a broad label indication for Oliceridine, without the need to do any further trials aside from the ongoing APOLLO studies in bunionectomy and abdominoplasty and the ATHENA multi procedure trial. A bunionectomy is a surgical procedure to remove a bunion, while an abdominoplasty is a cosmetic surgery procedure used to make the abdomen thinner, more commonly known as a "tummy tuck." LESS ADVERSE EFFECTS: Noting that millions of U.S. patients are treated with an intravenous opioid and have to deal with opioid related adverse effects, Gowen explained that Oliceridine was designed specifically to overcome these adverse events. The executive pointed out that Trevena's clinical data, so far, has shown that Oliceridine can deliver a very rapid pain relief at similar levels to morphine, but with fewer opioid related adverse effects, which she believes will improve hospital care for patients. OTHER PRODUCT CANDIDATES: Aside from Oliceridine, Trevena is developing TRV250 for the treatment of episodic migraine and TRV734 for moderate to severe acute and chronic pain. The CEO expects to submit an Investigational New Drug, or IND, application for '250 to the Food and Drug Administration later this year, which should enable the company to start clinical trials next year. Regarding TRV734, Gowen noted that it makes sense to evaluate a potential partnership as the commercialization of the drug for chronic pain is not "an ideal fit" for the company given Trevena's hospital and specialist focus. CAPITAL TO FUND OPERATIONS INTO 2018: The executive told The Fly that the company maintains its prior guidance, estimating to have enough capital to fund operations into 2018, adding that the company does not discuss plans for future financing. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. A more detailed version of this interview to follow.

  • 22

    Oct

  • 13

    Dec

TRVN Trevena
$6.03

0.11 (1.86%)

03/02/16
WBTH
03/02/16
INITIATION
Target $18
WBTH
Buy
Trevena initiated with a Buy at WallachBeth
WallachBeth analyst Caroline Palomeque started Trevena with a Buy rating and $18 price target. The company's lead candidate Oliceridine for post-operative acute pain may offer patients a treatment option with comparable analgesic efficacy, a faster onset of action and a more favorable safety profile than morphine, Palomeque tells investors in a research note.
03/02/16
03/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chemical Financial (CHFC) initiated with a Strong Buy at Raymond James by analyst David Long, who believes its pending accretive merger with Talmer Bancorp (TLMR) will provide the base for a more profitable company with strengthened growth prospects. 2. Infinity Pharmaceuticals (INFI) initiated with an Outperform at FBR Capital, with analyst Christopher James saying that duvelisib has the potential to be a first-in-class treatment for specific types of blood cancers. 3. Trevena (TRVN) initiated with a Buy at WallachBeth by analyst Caroline Palomeque, who said Oliceridine may offer patients a treatment option with comparable analgesic efficiency, a faster onset of action and a more favorable safety profile than morphine. 4. Aduro Biotech (ADRO) initiated with an Outperform at FBR Capital. 5. LKQ Corp. (LKQ) initiated with a Buy at Sterne Agee CRT. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/16
03/29/16
INITIATION
Target $16

Outperform
Trevena initiated with an Outperform at FBR Capital
FBR Capital analyst Christopher James started Trevena with an Outperform rating and $16 price target.
05/17/16
ROTH
05/17/16
NO CHANGE
Target $14.5
ROTH
Buy
Roth Capital remains a buyer of Trevena
Roth Capital analyst Michael Higgins reiterates a Buy rating and $14.50 price target on Trevena's shares. The analyst says the company announced that its TRV027 failed in Phase 2 and will be discontinuing the program. However, given the relative risk of development between its oliceridine and its TRV027, Higgins is not making any changes to his financial models. Trevena is "well-capitalized," with cash sufficient to fund operations for two years, the analyst tells investors in a research note, adding that he sees the company's shares as being at an "attractive entry point."

TODAY'S FREE FLY STORIES

07:16
01/23/18
01/23
07:16
01/23/18
07:16
Conference/Events
CFA Society of Columbus to hold a dinner meeting »

Ian Wallace of Third…

VYGR

Voyager Therapeutics

$20.23

1.56 (8.36%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Hot Stocks
Voyager Therapeutics announces FDA clearance of VY-AADC IND application »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBK

Triumph Bancorp

$37.00

1 (2.78%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Upgrade
Triumph Bancorp rating change  »

Triumph Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Conference/Events
Boston University to release survey »

Boston University…

CAT

Caterpillar

$170.89

0.48 (0.28%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Upgrade
Caterpillar rating change  »

Caterpillar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

GPRO

GoPro

$6.30

0.01 (0.16%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Downgrade
GoPro rating change  »

GoPro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:11
01/23/18
01/23
07:11
01/23/18
07:11
Periodicals
Verizon mulls sports gambling as legalization nears, Bloomberg reports »

Verizon is mulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

, JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Recommendations
Sorrento Therapeutics, Juno Therapeutics, Celgene analyst commentary  »

Juno acquisition bodes…

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

CELG

Celgene

$102.91

0.26 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 16

    Feb

  • 28

    Feb

  • 25

    Mar

SPX

S&P 500

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

, ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Conference/Events
U.S. Capital Advisors to hold a conference »

Midstream Corporate…

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 26

    Feb

ACBFF

Aurora Cannabis

$11.65

0.8799 (8.17%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Hot Stocks
Aurora Cannabis, CanniMed extending standstill agreement »

CanniMed Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.71

0.06 (0.25%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon up marginally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

AOS

A.O. Smith

$67.00

-0.04 (-0.06%)

, JCI

Johnson Controls

$39.20

0.3 (0.77%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Conference/Events
KeyBanc to hold company meetings at expo »

KeyBanc Company Meetings…

AOS

A.O. Smith

$67.00

-0.04 (-0.06%)

JCI

Johnson Controls

$39.20

0.3 (0.77%)

RBC

Regal Beloit

$79.20

-0.2 (-0.25%)

WTS

Watts Water

$79.65

-0.85 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 06

    Feb

  • 13

    Feb

  • 22

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Hot Stocks
Verizon sees positive impact to cash flow from operations from tax reform »

Tax-reform legislation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

GLD

SPDR Gold Trust

$126.65

0.23 (0.18%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:08
01/23/18
01/23
07:08
01/23/18
07:08
Conference/Events
Goldman Sachs to hold a conference »

Fintech Conference 2018…

NUGT

Direxion Gold Miners Bull

$32.99

0.15 (0.46%)

07:08
01/23/18
01/23
07:08
01/23/18
07:08
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.33

1.32 (1.17%)

07:08
01/23/18
01/23
07:08
01/23/18
07:08
Hot Stocks
Breaking Hot Stocks news story on JPMorgan »

JPMorgan hiring 4,000…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

PG

Procter & Gamble

$91.89

0.82 (0.90%)

07:08
01/23/18
01/23
07:08
01/23/18
07:08
Earnings
Procter & Gamble raises FY18 core EPS growth view to 5%-8% from 5%-7% »

P&G said it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:08
01/23/18
01/23
07:08
01/23/18
07:08
Earnings
Verizon sees FY18 revenue growth at low-single-digit percentage rate »

FY18 consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.04

0.11 (0.61%)

07:07
01/23/18
01/23
07:07
01/23/18
07:07
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRMN

Garmin

$64.04

0.17 (0.27%)

07:07
01/23/18
01/23
07:07
01/23/18
07:07
Hot Stocks
Garmin introduces Approach X10 GPS golf band »

Garmin International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DUST

Direxion Daily Gold Miners Bear 3X ETF

$22.02

-0.18 (-0.81%)

07:07
01/23/18
01/23
07:07
01/23/18
07:07
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.33

1.32 (1.17%)

07:06
01/23/18
01/23
07:06
01/23/18
07:06
Hot Stocks
Breaking Hot Stocks news story on JPMorgan »

JPMorgan expanding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.